| Trial ID: | L2157 |
| Source ID: | NCT01375491
|
| Associated Drug: |
Doxycycline
|
| Title: |
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
|
| Acronym: |
DOXY
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01375491/results
|
| Conditions: |
Type 2 Diabetes|Obesity
|
| Interventions: |
DRUG: Doxycycline|OTHER: Placebo
|
| Outcome Measures: |
Primary: MMP Activity, MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9., Baseline (Day 1)|MMP Activity, MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84., Day 84 | Secondary: CRP, Measure of global inflammation., Baseline (Day 1)|CRP, Measure of global inflammation. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84., Day 84
|
| Sponsor/Collaborators: |
Sponsor: University of California, San Diego | Collaborators: Ruth L. Kirschstein National Research Service Award|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
39
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-10
|
| Completion Date: |
2011-06
|
| Results First Posted: |
2020-01-13
|
| Last Update Posted: |
2020-01-13
|
| Locations: |
University of California San Diego Clinical trials Research Institute, La Jolla, California, 92093, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01375491
|
